Sirio Pharma (300791) — Cash Flow Reinvestment Rate
Sirio Pharma (300791) has a Cash Flow Reinvestment Rate of 0.78x as of June 2023, reinvesting CN¥79.56 Million (capex CN¥59.65 Million plus investments CN¥19.92 Million) from operating cash flow of CN¥101.61 Million. Check cash flow quality index of Sirio Pharma to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sirio Pharma Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Sirio Pharma across 8 annual periods. Explore Sirio Pharma cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Sirio Pharma (2017–2024)
Year-by-year capital reinvestment analysis for Sirio Pharma. For live market cap and broader valuation context, see market value of Sirio Pharma.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.31x | CN¥740.12 Million | CN¥566.97 Million | CN¥412.13 Million | ▼ -68.7% |
| 2023 | 4.17x | CN¥1.61 Billion | CN¥386.08 Million | CN¥451.70 Million | ▲ +90.5% |
| 2022 | 2.19x | CN¥973.69 Million | CN¥444.86 Million | CN¥293.69 Million | ▼ -2.0% |
| 2021 | 2.23x | CN¥762.68 Million | CN¥341.38 Million | CN¥524.68 Million | ▲ +72.8% |
| 2020 | 1.29x | CN¥413.14 Million | CN¥319.57 Million | CN¥223.14 Million | ▼ -49.8% |
| 2019 | 2.58x | CN¥596.90 Million | CN¥231.60 Million | CN¥166.90 Million | ▼ -29.4% |
| 2018 | 3.65x | CN¥669.32 Million | CN¥183.46 Million | CN¥239.32 Million | ▼ -69.5% |
| 2017 | 11.95x | CN¥589.82 Million | CN¥49.35 Million | CN¥159.82 Million | — |